       Document 0621
 DOCN  M9620621
 TI    [Therapeutic possibilities of recombinant interferon alfa-2b (Intron A)
       in non-AIDS Kaposi sarcomas and angiosarcomas]
 DT    9602
 AU    Jelic S; Vuletic L; Filipovic I; Milanovic N; Tomasevic Z; Marinkovic M;
       Institute of Oncology and Radiology, Belgrade.
 SO    Glas Srp Akad Nauka [Med]. 1994;(44):117-25. Unique Identifier :
       AIDSLINE MED/96021701
 AB    Data concerning treatment of vascular neoplasia with biological response
       modifiers are still scanty, but encouraging results have been observed
       with alpha-2b interferon in AIDS related Kaposi sarcoma. In this study
       five treatment naive patients with Kaposi sarcoma and four heavily
       pretreated patients with angiosarcoma with still evolutive disease were
       treated with Etopozid 120 mg/m2/24h, days 1, 3 and 5, and recombinant
       alpha-2b interferon 6.000.000 U/24h, days 1-15, the intercycle interval
       being 21-28 days. All patients were negative for anti-HIV 1, anti-HIV 2
       and anti-HTLV 1 antibodies; one patient had a high titer of IgG
       anti-chlamydia antibodies amounting to 1/4.194.304. This group differed
       from similar HIV 1 positive patients by having a normal CD4/CD8 ratio.
       In the Kaposi sarcoma group 1/5 achieved a complete response lasting 24+
       months and 3/5 achieved a good partial response lasting 5+, 12+ and 35+
       months. In the angiosarcoma group 1/4 patient achieved a complete
       response but relapsed after 18 months and one patient experienced stable
       disease lasting for 15+ months. These findings could be understood in
       two different ways. Since an infective etiology has been proposed for
       Kaposi sarcoma, the positive effect of alpha-2b interferon could be
       related to its antiinfective effects observed in viral disorders.
       However, similar activity in angiosarcoma points to the possibility that
       the positive effect of alpha-2b interferon in this group of disorders is
       related to interfering effects of the drug with factors implicated in
       neoplastic angiogenesis.
 DE    Adult  Aged  Combined Modality Therapy  CD4-CD8 Ratio  English Abstract
       Etoposide/THERAPEUTIC USE  Female
       Hemangiosarcoma/IMMUNOLOGY/SECONDARY/*THERAPY  Human  *HIV
       Seronegativity  Interferon Alfa-2b/*THERAPEUTIC USE  Male  Middle Age
       Sarcoma, Kaposi's/IMMUNOLOGY/*THERAPY  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

